sustainably produced

Our lead products, crofelemer (NP-303) and NP-300, are sustainably harvested utilizing fair trade practices, with the aim of ensuring a high degree of quality and ecological integrity.


Mytesi (crofelemer) is an anti-diarrheal drug indicated for symptomatic relief of non-infectious diarrhea in adults living with HIV/AIDS who are on antiretroviral therapy (ART).

important safety information

Mytesi is not indicated for the treatment of infectious diarrhea. Rule out infectious etiologies of diarrhea before starting Mytesi. If infectious etiologies are not considered, there is a risk that patients with infectious etiologies will not receive the appropriate therapy and their disease may worsen. In clinical studies, the most common adverse reactions occurring at a rate greater than placebo were upper respiratory tract infection (6%), bronchitis (4%), cough (4%), flatulence (3%), and increased bilirubin (3%).